Society for Immunotherapy of Cancer

SITC 2022 Logo
#Cancer research #Lung cancer #Oncology #Society for Immunotherapy of Cancer #Trial data

Immutep shares encouraging trial data at SITC 2022

Immutep has revealed encouraging initial clinical data from two trials investigating its lead product candidate eftilagimod alpha in non-small-cell lung cancer.  Findings from the trials were shared at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022.   The INSIGHT-003 trial is evaluating eftilagimod alpha… Read More

#Cancer Research #News